

《关于禁止发展、生产和储存细菌(生物)  
及毒素武器和销毁此种武器的公约》  
缔约国会议

11 June 2012  
Chinese  
Original: English

2012 年会议

2012 年 12 月 10 日至 14 日，日内瓦

专家会议

2012 年 7 月 16 日至 20 日，日内瓦

临时议程项目 6

常设议程项目：审查与《公约》有关的  
科学技术领域的发展

## 可增强能力的技术的进展

### 执行支助股提交的背景资料文件

#### 概要

第七次审查会议决定，在 2012-2015 年闭会期间方案中纳入一个关于审查与《公约》相关的科学技术领域发展的常设议程项目。会议还决定，在这一项目之下，2012 年缔约国将审议“可增强能力的技术的进展，包括下列方面的进展：用于 DNA 测序、合成和分析的高处理量系统；生物信息学和计算工具；和系统生物学”。本文件概述了可能相关的进展情况。本文件扩展并更新了为第七次审查会议编写的与《公约》相关的新的科学技术发展的背景资料文件(BWC/CONF.VII/INF.3 和增编)。附件仅有英文，介绍更为详细，并提到科学文献。

## 一. 分析生物系统和网络

1. 近年来在范围广泛的不同的“-组学”方面取得很大进展，例如基因组学(研究机体的所有遗传信息)，转录物组学(研究机体的全部 RNA)，蛋白质组学(研究机体的所有蛋白质)，代谢学(研究机体的全部生化过程或代谢过程)，以及这些组学如何相互联系。

2. 基因组学方面的进展包括：基因组宽度分析；在理解单核苷酸(SNP)多态性在疾病的作用方面取得进展；在理解复制数量变化在疾病的作用方面取得进展；功能基因组学；以及加强了对基因调控网络的参与性的理解。
3. 转录组学方面的进展包括：调节质的确定；调节质的分析；以及网络结构的意义。
4. 蛋白质组学方面的进展包括：更好地理解蛋白质如何合成；其存在随时间的波动情况；对于确保不能进行质量控制的序列提前终止的系统进行了更好的分析；协助确定和测定蛋白质数量的新的工具；数据报告更高的标准；改进了确定蛋白质结构的工具；提高了对蛋白质间相互作用的理解，例如通过测绘、调节、跨网络比较以及研究蛋白质信号级联。
5. 代谢学方面的进展包括：物种间路径的比较研究；扰乱和研究路径工具的改善；网络基序的调查；以及代谢网络(代谢流组)内代谢通量的研究。
6. 在将这些领域的数据结合起来方面也取得相当的进展，特别是在系统的测绘以及稍差一些的建模方面。或许结合不同方式的最好的例子是对脑炎支原体的分析，其中结合了基因组学、代谢学、蛋白质组学、结构信息以及分子信息。

## 二. 操控生物系统和网络

7. 过去五年里出现多方面进展，使之能更好地操控生物系统和网络。两个最重要的进展是 RNA 干扰技术(RNAi)和锌指核酸酶(ZFN)。

## 三. 制作生物系统和网络

8. 生物工程，或合成生物学，在过去五年中取得了相当大进展。工业对这些方法越来越感兴趣。可以制作的生物系统和网络的生物复杂性越来越高。
9. 除了控制细菌细胞的基因组的化学合成(克莱格·温特尔人工生命)，其他方法包括：通过在酵母中制作新陈代谢途径生产抗疟疾药物的前体；合成哺乳动物基因电路揭示抗结核化合物；广泛存在的生物计算的展示；以及制作大肠杆菌以探测和杀死人体内病原体。
10. 在克服已发现的限制合成生物学利用的技术障碍方面取得进展，包括分析片断；改善线路；解决复杂性问题；改善互用性；以及提高可靠性。在这方面有：技术改进；载体改进；研制新化合物。对于这些进展所涉安全问题也给予充分注意。
11. 生物化学的各种应用正在出现，包括：理解疾病机制、疾病预防、药品开发、新的传染病疗法、以及癌症疗法。

## 四. 收集和控制生物信息

12. 生物信息学和计算生物学方面的进展很大程度上促进了生物数据的收集、加工和利用，这包括创建新的语言；数据开发的进展；建模和模拟的改进，包括建立整细胞模拟；使复杂生物信息直观化和分析基因序列数据及蛋白质在线工具和软件以及工具的设计。各实验室正日益数字化。生物信息学方面的进展与分析技术、高通量方法以及机器人学相结合创造完全自动的研究机器人。计算机控制人工智能提出假设，在自动化试验室进行测试并将结果反馈至系统，以设计新一轮的试验。不仅研制机器人的科学家承诺将许多繁重的工作放在基础研究之外，他们还可能帮助解决在分析片断、确定功能和解释原始数据方面存在的瓶颈。

## 五. 将生物信息转变为数字数据或反向操作

13. 如果说生物学正在成为信息科学，那部分是因为它有能力强将生物数据转变为数字数据然后再转变回来。基因测序(解读基因编码)使研究人员能沿一个方向前进，而基因合成(编写基因密码)则是另一方向。解读和编写基因密码的能力并不是新的，但确实这些领域在过去五年中发生了巨大的变化。

14. 在过去五年中，第二代和第三代测序器已经制造出来。这使最初的测序能力有很大的提高。现代机器在 1 天之内就能测出一个人类基因组的序列。一个人类基因组测序的费用已降至 1,000 美元以下。这使人们能开始尝试新型项目并收集不同种类的数据。在 2006 年第六次审查会议上，仅对两个人类基因组进行了测序。截至 2011 年 10 月，已经对 13,000 多个人类基因组进行了测序。

15. 这一扩大的测序能力的各种新的保健应用正在被发现，包括在诊断和指导疗法方面。政府和私营部门在开发新的应用、工具和平台方面都做了大量投资。

16. 合成能力的趋势也反映出测序方面的趋势。制造更长的基因材料链的能力方面出现了技术上的改进。新的组合技术能够更容易和更快地将短的片断结合成长的序列。商业合成基因片断的费用也持续下降。测序材料的质量似乎也在提高。这导致开始尝试更加复杂的项目。在过去五年中，遗传材料的合成从有关病毒、细菌、哺乳动物细胞器官到利用真核细胞部分合成染色体。

## 六. 一般使能技术

17. 支撑本文件所讨论的各种进步的是一系列的技术，这些技术使之能更容易、廉价、迅速和更可靠地实行许多基本程序和做法，扩展目前的理解并创造新的应用方法。其他一些进展使科学家能够做以前不能做到的事情。过去五年以来已经发展了很大范围的新的使能技术。

## Annex

[ENGLISH ONLY]

### Advances in enabling technologies: a more detailed review

#### I. Characterizing biological systems and networks

1. Considerable progress has been made in recent years across a broad range of different "-omics", such as genomics (the study of all the genetic information in an organism), transcriptomics (the study of all the RNA in an organism), proteomics (the study of all the proteins in an organism), metabolomics (the study of all the biochemical processes or metabolism of an organism), as well as how they relate to one and other.

2. Genomic advances have included: a deeper understanding of the importance of "junk" genetic material<sup>1</sup>; a more sophisticated appreciation of how and why genes are expressed, through epigenomics<sup>2</sup>; developments in identifying genetic interactions, especially through the use of RNAi;<sup>3</sup> a better understanding of impact of mutations in hotspots, (or quantitative trait loci) on the downstream expression of distant genes;<sup>4</sup> and new techniques to identify novel or rare genomes from collected genomic data.<sup>5</sup> Advances related to genome wide analysis have:<sup>6</sup> enabled the simultaneous analysis of single nucleotide polymorphisms (SNPs) to identify higher level interactions;<sup>7</sup> led to efforts to understand how SNPs relate to disease; provided new insights in transcription;<sup>8</sup> as well as provided insights into the genetic component of social behaviour.<sup>9</sup> One example of a study that has linked genomics to disease was the investigation of SNP variation in the genomic epidemiology of malaria.<sup>10</sup> Parallel progress in the implications of copy number variations include: their role in gene and genome evolution; their impact on gene expression profiles; as well as their relationship with disease.<sup>11</sup> There have also been advances in functional genomics,<sup>12</sup> such as: creating a genome wide functional map of genes in a mammal; using evolutionary developmental biology to help bridge the gap between genetic information and physical characteristic; and in using RNAi to understand epistatic genetic interactions.<sup>13</sup> There has also been considerable development of concepts of the evolvability of gene regulatory networks.<sup>14</sup> Research has shown, for example, how gene networks develop

---

<sup>1</sup> <http://www.newscientist.com/article/dn14667-junk-dna-may-have-handed-us-a-gripping-future.html>

<sup>2</sup> <http://www.nature.com/news/2010/100510/full465145a.html>

<sup>3</sup> <http://www.nature.com/nmeth/journal/v8/n4/full/nmeth.1581.html>

<sup>4</sup> <http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000232>

<sup>5</sup> <http://www.sciencemag.org/content/335/6068/587.abstract>

<sup>6</sup> <http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1000218>

<sup>7</sup> <http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000130>

<sup>8</sup> <http://www.nature.com/nature/journal/v483/n7389/abs/nature10799.html>

<sup>9</sup> <http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000127>

<sup>10</sup> <http://www.nature.com/nature/journal/v456/n7223/full/nature07632.html>

<sup>11</sup> <http://www.annualreviews.org/doi/abs/10.1146/annurev.genom.9.081307.164217>

<sup>12</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000165>

<sup>13</sup> <http://www.nature.com/nmeth/journal/v8/n4/full/nmeth0411-299.html>

<sup>14</sup> <http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1000112>

robustness through the application of selective pressures, such as provided by host-parasite interactions.<sup>15</sup>

3. Advances in transcriptomics can be roughly broken down into the identification of regulators, the characterization of regulators, and those that relate to network structure.<sup>16</sup> Studies released over the past five years have identified a number of transcriptomic regulators, such as microRNAs (miRNAs), piwi-interacting RNAs, and small interfering RNA (siRNA).<sup>17</sup> Our understanding of the roles played by such regulators has also expanded including: in explaining the comparative complexity of different organisms; in regulating gene expression; in evolutionary development; and in determining the phenotypic (physical) properties of plants. Progress has been made in characterizing regulators, including a quantitative comparison of the short RNA-based systems and protein-based gene regulation.<sup>18</sup> There has also been an advance in our understanding of the role of large intergenic non-coding RNAs (lincRNAs) which have been shown to regulate gene expression. Studies of the control networks for transcription have highlighted that their topography has implications for function.<sup>19</sup> They seem to be organised to avoid malfunctions. Their robustness also seems to be linked to their structure, specifically the volume and geometry of flexible regions in the parameter space.<sup>20</sup>

4. Considerable progress has been made across the field of proteomics. Understanding of how proteins are synthesised, for example, has been supplemented by better characterization of the system which ensures the premature termination of sequences that fail quality control.<sup>21</sup> Other advances have helped explain how protein composition changes over time, for example, through insights into the structure and function of enzymes responsible for their degradation.<sup>22</sup> There have been new tools assist in the identification and quantification of proteins,<sup>23</sup> such as: electron-vibration-vibration two-dimensional infrared spectroscopy; and advances in mass spectrometry. Guidelines have also been developed for facilitate the standardization of data reporting in proteomics, including for mass spectrometry and gel electrophoresis. In terms of determining the structure of proteins, there have been a series of advances in developing high-throughput approaches,<sup>24</sup> including in detecting mature and changing forms of proteins.<sup>25</sup> Similar advances have enabled the structures of "once-intractable" proteins to be identified.<sup>26</sup> Structural comparisons of proteins in different species have also enabled researchers to make headway in determining the function of specific proteins.<sup>27</sup> Perhaps the area of greatest interest has been in working on protein-protein interactions (PPI) with progress being made in mapping, regulation, cross network comparisons and protein signalling cascades.<sup>28</sup>

5. PPI maps have been generated using high-throughput microfluidic approaches. Additional details have been added from studying mRNAs.<sup>29</sup> These maps have improved

<sup>15</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516366/>

<sup>16</sup> <http://www.nature.com/nature/journal/v455/n7217/full/4551184a.html>

<sup>17</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583084/>

<sup>18</sup> <http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10398.html>

<sup>19</sup> <http://phys.org/news192128818.html>

<sup>20</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000256>

<sup>21</sup> <http://www.nature.com/nature/journal/v457/n7226/full/457157a.html>

<sup>22</sup> <http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10774.html>

<sup>23</sup> <http://www.nature.com/nmeth/journal/v5/n12/full/nmeth1208-993.html>

<sup>24</sup> [http://www.sciencemag.org/site/products/lst\\_20080801.xhtml](http://www.sciencemag.org/site/products/lst_20080801.xhtml)

<sup>25</sup> <http://www.nature.com/nature/journal/v480/n7376/full/nature10575.html>

<sup>26</sup> <http://www.nature.com/news/opioid-receptors-revealed-1.10273>

<sup>27</sup> <http://www.biomedcentral.com/1752-0509/2/69>

<sup>28</sup> <http://www.ncbi.nlm.nih.gov/pubmed/19098921>

<sup>29</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387231/>

our understanding of cellular organization and function.<sup>30</sup> They could also act as an important resource for annotating the proteome.<sup>31</sup> Considerable effort has gone into refining the topology of maps, including the roles of: hubs; and randomness.<sup>32 33</sup> The importance of including structural information in the maps, for example, has been demonstrated.<sup>34</sup> The regulation of PPI has led to improvements in our understanding of how protein complexes form.<sup>35</sup> The constraints placed upon PPIs by non-functioning interactions have also been investigated.<sup>36</sup> Research released over the past five years links the regulation of PPI to innate immunity.<sup>37</sup> By studying protein interaction networks in different organisms, researchers have been able to identify conserved protein function.<sup>38</sup> Published results also highlight recurring design patterns in network design.<sup>39</sup> There are also shared mechanisms within the various network schemas.<sup>40</sup> There have also been a range of advances relating to the characterization of protein signalling cascades. One group examined dynamic capabilities and used the results to help them identify functions.<sup>41</sup> A second group both quantified information exchange and determined channel noise and capacity.<sup>42</sup> Insights into the regulation of protein signalling cascades have come from investigating the roles of signal duration.<sup>43</sup>

6. The field of metabolomics is evolving from "cataloguing metabolites to asking broader biological questions about how metabolites reflect and affect cell function".<sup>44</sup> For example, comparing metabolic pathways between species provides information on their evolution, can assist in metabolic engineering and may assist in analysing diseases and designing drugs.<sup>45</sup> There have been advances in the tools available to study metabolomics, including allowing the targeting of simultaneous perturbations to determine the structure and function of networks.<sup>46</sup> The study of certain network motifs has facilitated determination of how and when certain pathways within networks are used.<sup>47</sup> Research has also indicated that fluxes within metabolic networks (the study of which is sometimes called fluxomics) are connected to health and disease.<sup>48</sup> The related field of studying "the global, dynamic metabolic response of living systems to biological stimuli or genetic manipulation" (metabonomics) has the potential to offer insights into disease networks and assist in drug discovery.<sup>49</sup>

7. Some of the most insightful advances have resulted when data from two or more of these approaches has been combined. For example, structure network analysis has provided

<sup>30</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18949022>

<sup>31</sup> <http://www.ncbi.nlm.nih.gov/pubmed/16169070>

<sup>32</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000114>

<sup>33</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000140>

<sup>34</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290937/>

<sup>35</sup> <http://www.biomedcentral.com/1752-0509/3/3>

<sup>36</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538908/>

<sup>37</sup> <http://genomebiology.com/2008/9/8/R123>

<sup>38</sup> <http://www.pnas.org/content/105/35/12763.full>

<sup>39</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424294/>

<sup>40</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18949022>

<sup>41</sup> <http://www.nature.com/nchembio/journal/v4/n11/full/nchembio1108-643.html>

<sup>42</sup> <http://www.ncbi.nlm.nih.gov/pubmed/19149897>

<sup>43</sup> <http://www.biomedcentral.com/1752-0509/2/108>

<sup>44</sup> <http://www.nature.com/nmeth/journal/v8/n2/full/nmeth0211-117.html>

<sup>45</sup> <http://www.biomedcentral.com/1752-0509/2/111>

<sup>46</sup> <http://www.nature.com/nbt/journal/v27/n2/full/nbt0209-149.html>

<sup>47</sup> <http://www.nature.com/nbt/journal/v26/n11/abs/nbt.1499.html>

<sup>48</sup> <http://www.nature.com/nbt/journal/v26/n10/full/nbt1008-1090.html>

<sup>49</sup> <http://www.nature.com/nature/journal/v455/n7216/full/4551054a.html>

insights into protein-DNA interactions.<sup>50</sup> Graph alignment of protein and genetic information has provided for additional functional data in at least one pathogen.<sup>51</sup> Another study that made use of protein-DNA interactions produced models for the feedback control of single genes and pairs of genes (toggle switches).<sup>52</sup> Additionally, studies that combined both metabolomic and proteomic data have demonstrated that the relationship between the two can be asymmetrical.<sup>53</sup> A second group used similar sets of data to identify novel molecular organizing principles.<sup>54</sup>

8. There have been significant advances in mapping and modelling networks based upon mixed data sets. One map of a cancer-causing pathway, for example, included information on proteins, genes, protein complexes, chemical compounds and biochemical reactions.<sup>55</sup> Creating these maps allows for the identification of higher-order combination effects (where contributing components are found in different approaches).<sup>56</sup> Mapping efforts have also begun to evolve into modelling attempts. One group reported developing a genome-scale kinetic model which combines genomic data with metabolic data and fluxomic data.<sup>57</sup>

9. Perhaps one of the most impressive examples of what can be achieved through combining these different approaches was the characterization of *Mycoplasma pneumoniae* which included the integration of genomic, metabolic, proteomic, structural and cellular information.<sup>58</sup> Combining -omics can also provide direct insights into disease. There have been efforts to reverse engineer the networks responsible for complex diseases.<sup>59</sup> Researchers have also reported the development of a computational framework that integrates proteomic information, similarities in disease phenotype and known gene-phenotype associations to assist in identifying currently unknown disease-related genes.<sup>60</sup>

## II. Manipulating biological systems and networks

10. There have been a variety of developments over the last five years that enable greater control in manipulating biological systems and networks. Researchers have proven successful in unlocking capacity in such systems, for example, by reactivating latent viruses.<sup>61</sup> There have also been practical advances in sidestepping interruptions in metabolic networks — either by bypassing the affected genes or by compensating for functions via network manipulation.<sup>62</sup> Researchers have also developed our abilities to manipulate the growth rates of cellular cultures<sup>63</sup> and to manipulate muscle mass and exercise endurance in animals.<sup>64</sup> There have also been significant developments in ability to

<sup>50</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000170>

<sup>51</sup> <http://www.biomedcentral.com/1752-0509/2/90>

<sup>52</sup> <http://www.biomedcentral.com/1752-0509/2/94>

<sup>53</sup> <http://genomebiology.com/content/10/2/R19>

<sup>54</sup> <http://www.biomedcentral.com/1752-0509/2/100>

<sup>55</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18319725>

<sup>56</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538911/>

<sup>57</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290940/>

<sup>58</sup> [http://www.embl.de/aboutus/communication\\_outreach/media\\_relations/2009/091127\\_Heidelberg/](http://www.embl.de/aboutus/communication_outreach/media_relations/2009/091127_Heidelberg/)

<sup>59</sup> <http://www.biomedcentral.com/1752-0509/2/72>

<sup>60</sup> <http://www.nature.com/msb/journal/v4/n1/full/msb200827.html>

<sup>61</sup> <http://online.wsj.com/article/SB10001424052748704529204576256714090044534.html>

<sup>62</sup> <http://www.nature.com/msb/journal/v4/n1/full/msb20081.html>

<sup>63</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000257>

<sup>64</sup> <http://www.cell.com/abstract/S0092-8674%2811%2901223-2>

engineer controls for networks.<sup>65</sup> One group has reported rewiring RNA machinery to include an on/off switch that can be manipulated by the addition of endogenous proteins. The proof-of-principle has been built into human T-cells.<sup>66</sup> A second team engineered a light-activated on-off switch for use in animal models.<sup>67</sup> The discovery of novel inter-cellular communication channels in bacteria also offers additional routes to add information into, or take it out of these systems.<sup>68</sup> The two most significant advances in this area, however, have been with RNAi technology and Zinc Finger Nucleases (ZFN).

11. RNAi is a mechanism which silences individual genes. It is used in nature as one of the many small RNAs that regulates transcription. It is a powerful research tool as it enables the direct perturbation of the genetic network by being programmed to silence virtually any genetic sequence. Over the past five years considerable progress has been made in understanding its biochemical and biophysical properties and describing the various mechanism by which it works.<sup>69</sup> RNAi has been used in public health research, for example, to examine how drugs to treat African sleeping sickness enter cells and exert biological effects.<sup>70</sup> There have also been advances that facilitate more programmable control over RNAi, especially through model-guided design.<sup>71</sup> There has been considerable interest in the therapeutic potential of RNAi.<sup>72</sup> For example, the World Organization for Animal Health has highlighted its potential for combating foot-and-mouth disease and in interfering with influenza infections in poultry. Recent years have seen large pharmaceutical companies turning away from developing RNAi-based therapies.<sup>73</sup> Smaller companies are making progress in developing RNAi-based products.<sup>74</sup> Studies of patent applications, and patents granted, however, suggest that there is still significant commercial interest in this technology.<sup>75</sup> One of the technical challenges to developing RNAi-based therapeutics has been getting it inside cells. In July 2011, a research team reported have created a new nanoparticle-based delivery system that might overcome this hurdle.<sup>76</sup>

12. ZFNs are a powerful genome engineering tool which can be targeted to a particular genomic domain, cuts both strands of the DNA and allows for donor DNA to be added instead.<sup>77</sup> This enables both gene deletion and site-specific mutations. ZFNs have been used to delete up to 15 million bases of information. Until very recently they have been difficult to design and produce. It has been a task left to specialist contractors.<sup>78</sup> Three papers published in early 2011 report: more streamlined production via context-dependent assembly (CoDA) which might open doors to in house production of ZFN;<sup>79</sup> the re-engineering of the dimerization interface creating higher levels of cleavage activity; and improved modular assembly techniques.<sup>80</sup> These papers could open the door for the much

---

<sup>65</sup> <http://www.nature.com/nmeth/journal/v8/n2/full/nmeth0211-108a.html>

<sup>66</sup> <http://www.technologyreview.com/biomedicine/25237/>

<sup>67</sup> <http://dev.biologists.org/content/139/9/1691>

<sup>68</sup> [http://www.cell.com/abstract/S0092-8674\(11\)00016-X](http://www.cell.com/abstract/S0092-8674(11)00016-X)

<sup>69</sup> <http://www.jbc.org/content/284/27/17897>

<sup>70</sup> <http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10771.html>

<sup>71</sup> <http://www.nature.com/msb/journal/v4/n1/full/msb200862.html>

<sup>72</sup> <http://www.oie.int/doc/document.php?numrec=3638903>

<sup>73</sup> <http://www.nature.com/news/2011/110803/full/476010a.html>

<sup>74</sup> <http://www.genengnews.com/gen-articles/use-of-sirna-in-therapeutic-arena-on-the-upswing/4072/>

<sup>75</sup> <http://www.nature.com/nbt/journal/v29/n6/full/nbt.1885.html>

<sup>76</sup> <http://www.masshightech.com/stories/2011/07/25/daily10-Alnylam-and-MIT-publish-RNAi-nanoparticle-findings.html>

<sup>77</sup> <http://www.nature.com/nmeth/journal/v8/n1/full/nmeth.f.328.html>

<sup>78</sup> <http://www.nature.com/nmeth/journal/v8/n1/full/nmeth.1542.html>

<sup>79</sup> <http://www.nature.com/nmeth/journal/v8/n1/full/nmeth0111-53.html>

<sup>80</sup> <http://www.nature.com/nmeth/journal/v8/n1/full/nmeth.1539.html>

wider use of this technology. One stumbling block yet to be overcome is the patent estate associated with this technology. One company now controls the majority of associated intellectual property.<sup>81</sup> Whilst this will likely impact upon opportunities for the commercial development of any discovery made with this system, it is unclear what the implications might be for its use as a research tool.<sup>82</sup>

### III. Engineering biological systems and networks

13. Biological engineering, or synthetic biology, has advanced considerably over the past five years. Industry is becoming increasingly interested in these approaches. Synthetic biology has evolved from a field with a great deal of potential, to an approach that is already yielding concrete examples of its potential power (but still with a great deal of potential to grow further). In addition to the chemical synthesis of a genome able to control a bacterial cell (Craig Venter's artificial life) other important stepping stones include: the engineering of the metabolic pathway in yeast to produce the precursor of an anti-malarial drug,<sup>83</sup> the creation of a synthetic mammalian gene circuit that revealed anti-tuberculosis compounds,<sup>84</sup> a demonstration of distributed biological computation; and the engineering of an *E. coli* to sense and kill a human pathogen.<sup>85</sup>

14. The complexity of what can be accomplished using synthetic biology has been increasing.<sup>86</sup> Traditional genetic engineering approaches, which involved the engineering of single genes, were supplemented by metabolic pathway engineering, such as new modular circuits for gene transcription or engineer *E. coli* to produce putrescine.<sup>87</sup> Metabolic pathway engineering was supplemented by the ability to engineer entire organisms, for example engineering *E. coli* to be able to solve mathematical puzzles like the Burnt Pancake Problem or the Hamilton Path Problem.<sup>88, 89</sup> Benign viruses have been re-engineered into assembly devices.<sup>90</sup> More recently, the ability to engineer individual organisms has been supplemented with capabilities to engineer collectives of organisms,<sup>91</sup> for example to synchronize blinking patterns or to model a predator-prey ecosystem.<sup>92</sup> Subsequent research has significantly increased the size of colony which can be controlled<sup>93</sup> and the complexity of the behaviour which can be encoded.<sup>94</sup>

15. There are still hurdles to be overcome if biological engineering is going to live up to its full potential. In January 2010 an article in Nature set out five grand challenges:

- (a) Many of the parts continue to be uncharacterized;
- (b) The 'wiring' of biological circuits remains unpredictable;
- (c) The complexity of systems make them difficult to manipulate;

<sup>81</sup> <http://www.nature.com/nbt/journal/v27/n2/abs/nbt0209-140.html>

<sup>82</sup> <http://www.nature.com/nmeth/journal/v8/n1/full/nmeth0111-7a.html>

<sup>83</sup> <http://www.sciencemag.org/content/329/5987/52.abstract>

<sup>84</sup> <http://www.pnas.org/content/105/29/9994.abstract>

<sup>85</sup> <http://www.nature.com/msb/journal/v7/n1/full/msb201155.html>

<sup>86</sup> <http://www.jbioleng.org/content/4/1/14>

<sup>87</sup> <http://www.ncbi.nlm.nih.gov/pubmed/19714672>

<sup>88</sup> <http://www.jbioleng.org/content/2/1/8>

<sup>89</sup> <http://www.jbioleng.org/content/2/1/8>

<sup>90</sup> <http://www.nature.com/nature/journal/v478/n7369/abs/nature10513.html>

<sup>91</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18414488>

<sup>92</sup> <http://www.sciencemag.org/content/333/6047/1315>

<sup>93</sup> <http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature10722.html>

<sup>94</sup> <http://www.pnas.org/content/early/2011/09/19/1109554108.abstract>

- (d) Many of the parts do not work together as expected; and
- (e) Circuits tend not to be reliable thanks to variability.<sup>95</sup>

There has been progress in addressing these challenges. The development of standards for characterization will help to address undefined parts — although there is a great deal of laboratory work to be done on implementing this.<sup>96</sup> Efforts to address the wiring challenge have included: efforts to improve the separation of signal from noise;<sup>97</sup> efforts to reduce biological noise;<sup>98</sup> efforts to work with biological noise;<sup>99</sup> efforts to produce noise-tolerant and delay-robust gene circuits;<sup>100</sup> as well as efforts to incorporate distributed robustness.<sup>101</sup> Improvements in identifying and defining modularity will help to address the levels of complexity involved.<sup>102</sup> Research has also demonstrated that the basic principles of a bottom-up approach to biological engineering work with sufficient modelling and characterization.<sup>103</sup> This suggests that as capabilities in these areas increase, issues of the incompatibility of parts might decrease. Reliability issues are slowly being addressed by improvements in designing evolutionary robust gene circuits and in stabilizing synthetic data in the DNA of living organisms.<sup>104,105</sup>

16. Over the past five years, there have also been advances in: the protocols available for synthetic biology, such as improvements in how synthetic gene circuits can be assembled and optimised;<sup>106</sup> design tools, such as the creation of a computer-aided design tool for synthetic biology;<sup>107</sup> as well as the availability of parts,<sup>108</sup> in terms of the creation of professional facilities to produce parts, developments in the intellectual property frameworks that govern use of those parts, and calls for the publication of full sequence data for synthetic sequences, facilitating the recreation of parts.<sup>109</sup>

17. There have also been advances in the chassis developed for use in synthetic biology.<sup>110</sup> The potential for host physiology to modulate engineered gene circuits highlights the importance of developing efficient chassis. Mechanisms to insulate engineered metabolic circuits from host circuitry have also been demonstrated.<sup>111</sup> Published research suggests that while considerable progress towards a minimal cell chassis has come a long way, there is much still to do before it is ready for wide-scale use.<sup>112</sup> There has also been significant progress in re-engineering standard research and industrial microbes, such as *E. coli* and *S. cerevisiae*, to make them more suitable for use as chassis.<sup>113</sup>

<sup>95</sup> <http://www.nature.com/news/2010/100120/full/463288a.html>

<sup>96</sup> <http://www.jbioleng.org/content/3/1/4>

<sup>97</sup> <http://www.pnas.org/content/early/2012/04/20/1119407109.abstract>

<sup>98</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000167>

<sup>99</sup> <http://www.ploscompbiol.org/article/info:doi%2F10.1371%2Fjournal.pcbi.1000125>

<sup>100</sup> <http://www.biomedcentral.com/1752-0509/2/103>

<sup>101</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18796402>

<sup>102</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267732/>

<sup>103</sup> <http://www.jbioleng.org/content/4/1/14>

<sup>104</sup> <http://www.jbioleng.org/content/4/1/12>

<sup>105</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671590/>

<sup>106</sup> <http://www.jbioleng.org/content/4/1/17>

<sup>107</sup> <http://www.jbioleng.org/content/3/1/19>

<sup>108</sup> <http://www.nature.com/news/2010/100722/full/news.2010.367.html>

<sup>109</sup> <http://www.nature.com/nbt/journal/v29/n1/full/nbt.1753.html>

<sup>110</sup> <http://www.nature.com/nchembio/journal/v5/n11/abs/nchembio.218.html>

<sup>111</sup> <http://www.jbioleng.org/content/4/1/3>

<sup>112</sup> <http://www.nature.com/msb/journal/v2/n1/full/msb4100090.html>

<sup>113</sup> [http://www.nsf.gov/news/news\\_summ.jsp?cntn\\_id=121639](http://www.nsf.gov/news/news_summ.jsp?cntn_id=121639)

18. The last few years have also seen the development of a range of different components that could be used with — or independently from — such chassis, including: rewired genetic switches;<sup>114</sup> functional molecules, such as re-engineered ribosomes; cell-free metabolic platforms for protein production;<sup>115</sup> non-natural synthetic proteins;<sup>116</sup> synthetic cell membranes;<sup>117</sup> as well as a self destruct mechanism to prevent engineered organisms surviving outside of laboratory settings.<sup>118</sup> A 2012 review of components included: regulatory cascades; epigenetic toggle switches; hysteretic circuits; molecular timing devices; synthetic eco-sensing systems; synthetic quorum-sensing systems; synthetic hormone systems; band-pass filters; as well as oscillators with tuneable frequency and amplitude.<sup>119</sup>

19. The same review noted that "a decade after the pioneering synthetic networks were reported, the first successful therapeutic applications in animal models of prominent human diseases are starting to emerge".<sup>120</sup> These studies include the "first synthetic closed-loop control gene network that manages homeostasis of a crucial disease metabolite in an animal model" and the "first optogenetic device that controls the production of a therapeutic protein in an animal disease model". It also examines other emerging biomedical applications, including for: understanding disease mechanisms, such as pathogen mechanisms and the immune system; disease prevention, such as vaccines and vector control; drug development, such as drug discovery, production and delivery; novel treatments for infections, such as breaking bacterial resistance and engineering pro-biotic bacteria to decrease pathogen virulence; cancer therapies, such as bacterial synthetic devices, viral synthetic devices and transformation sensors for cancer therapy; and other aspects, such as RNA controllers for cell proliferation, optogenetic devices in blood glucose homeostasis and prosthetic networks.

20. One challenge to the eventual wide-scale use of technology derived from synthetic biology will be the control of agents following release. Considerable work has already been undertaken to create kill switches designed to prevent undesirable spread.<sup>121</sup> Similar approaches are already yielding results in other fields.<sup>122</sup>

21. The safety and security implications of synthetic biology have been examined closely in parallel with scientific and technological developments.<sup>123</sup> Concerns have already been raised over military investment in synthetic biology.<sup>124</sup> Key reports published since 2006 include:

(a) *New Directions: The Ethics of Synthetic Biology and Emerging Technologies* by the Presidential Commission for the Study of Bioethical Issues in the United States;<sup>125</sup>

(b) *Synthetic Biology: the Technoscience and its Societal Consequences* by the SYNBIOSAFE project;<sup>126</sup>

<sup>114</sup> <http://www.sciencedaily.com/releases/2010/01/100125173244.htm>

<sup>115</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583083/>

<sup>116</sup> <http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0015364>

<sup>117</sup> <http://www.technologyreview.com/news/423381/making-cells-on-an-assembly-line/>

<sup>118</sup> <http://www.ncbi.nlm.nih.gov/pubmed/21645422>

<sup>119</sup> <http://www.nature.com/nrg/journal/v13/n1/abs/nrg3094.html>

<sup>120</sup> <http://www.nature.com/nrg/journal/v13/n1/abs/nrg3094.html>

<sup>121</sup> <http://www.pnas.org/content/early/2010/08/09/1009747107.abstract>

<sup>122</sup> <http://www.nejm.org/doi/full/10.1056/NEJMoa1106152>

<sup>123</sup> <http://www.livescience.com/10715-synthetic-biology-great-promise-potential-peril.html>

<sup>124</sup> <http://www.nature.com/news/bioengineers-debate-use-of-military-money-1.9409>

<sup>125</sup> <http://www.bioethics.gov/documents/synthetic-biology/PCSBI-Synthetic-Biology-Report-12.16.10.pdf>

- (c) *Synthetic Biology: Social and Ethical Challenges* by the Institute for Science and Society;<sup>127</sup>
- (d) *Synthesis Report on Opportunities and Challenges in the Emerging Field of Synthetic Biology* by the Organization for Economic Cooperation and Development and the Royal Society;<sup>128</sup>
- (e) *Risk Governance of Synthetic Biology* by the International Risk Governance Council;<sup>129</sup>
- (f) *Synthetic Biology: Scope, Applications and Implications* by the Royal Academy of Engineering;<sup>130</sup>
- (g) *What Rough Beast? Synthetic Biology, Uncertainty, and the Future of Biosecurity*, by academics at the Massachusetts Institute of Technology and Boston University;<sup>131</sup>
- (h) *Security Implications of Synthetic Biology and Nanobiotechnology* by the United Nations Interregional Crime and Justice Institute (UNICRI);<sup>132</sup>
- (i) *The Transnational Governance of Synthetic Biology: Scientific Uncertainty, Cross-borderness and the Art of Governance* by the London School of Economics and Political Science;<sup>133</sup> and
- (j) *Synthetic Biology: Four Steps to Avoid a Synthetic Biology Disaster* by the Woodrow Wilson International Center for Scholars.<sup>134</sup>

In general, these reports recognise that synthetic biology "appears to have minimal security implications in the near term, create modest offensive advantages in the medium term, and strengthen defensive capabilities against natural and engineered biological threats and enable novel potential offensive uses in the long term".<sup>135</sup> Similar findings were echoed in the UNICRI review published in 2011.

#### IV. Gathering and manipulating biological information

22. Advances in bioinformatics and computational biology have greatly aided the gathering, processing and utility of biological data. Laboratories are becoming increasingly digitized.<sup>136</sup> This has helped extract information that was previously obscured and has made it easier and quicker to accomplish certain tasks. Increasingly the life sciences are referred to as information sciences. Digital tools and platforms not only support laboratory work but are increasingly able to replace it.

23. Descriptive languages developed over the last few years have included: a language for standardising and automating biology protocols: as well as a modelling language

<sup>126</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671589/>

<sup>127</sup> [http://www.bbsrc.ac.uk/web/FILES/Reviews/0806\\_synthetic\\_biology.pdf](http://www.bbsrc.ac.uk/web/FILES/Reviews/0806_synthetic_biology.pdf)

<sup>128</sup> <http://www.oecd.org/dataoecd/23/49/45144066.pdf>

<sup>129</sup> [http://www.irgc.org/IMG/pdf/IRGC\\_Concept\\_Note\\_Synthetic\\_Biology\\_191009\\_FINAL.pdf](http://www.irgc.org/IMG/pdf/IRGC_Concept_Note_Synthetic_Biology_191009_FINAL.pdf)

<sup>130</sup> [https://www.cbd.int/doc/emerging-issues/UK-submission-2011-013-Synthetic\\_biology-en.pdf](https://www.cbd.int/doc/emerging-issues/UK-submission-2011-013-Synthetic_biology-en.pdf)

<sup>131</sup> [http://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=1452053](http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1452053)

<sup>132</sup> <http://igem.org/wiki/images/e/ec/UNICRI-synNanobio-final-2-public.pdf>

<sup>133</sup> [http://royalsociety.org/uploadedFiles/Royal\\_Society\\_Content/policy/publications/2011/4294977685.pdf](http://royalsociety.org/uploadedFiles/Royal_Society_Content/policy/publications/2011/4294977685.pdf)

<sup>134</sup> <http://www.nature.com/nature/journal/v483/n7387/full/483029a.html>

<sup>135</sup> [http://www.bioone.org/doi/abs/10.2990/28\\_2\\_2](http://www.bioone.org/doi/abs/10.2990/28_2_2)

<sup>136</sup> <http://www.nature.com/news/going-paperless-the-digital-lab-1.9881>

derived from one used in artificial intelligence that allows for better descriptions of biological processes.<sup>137</sup>

24. Advances in data mining have included: using multiple applications and datasets to reveal additional information about a system;<sup>138</sup> using Boolean logic to help identify genes; merging network theory and microarray data to reveal information about the co-expression of genes;<sup>139</sup> and tools for identifying interesting relationships between pairs of variables in large data sets.<sup>140</sup>

25. Capabilities in modelling and simulation have advanced significantly, including in: incorporating non-linear complexity, such as by adopting enzyme-centric approaches; as well as combining rule-based representations with agent-based simulation.<sup>141</sup>

26. It is now possible to recreate and in some cases make predictions from computational representations of: pathogenicity in fungi;<sup>142</sup> gene circuits, including filling in gaps that cannot be measured experimentally;<sup>143</sup> protein-protein interactions from amino acid sequence data and network structure;<sup>144</sup> biochemical and diffusion reactions both in parts of cells and in whole cell contexts;<sup>145</sup> metabolic networks (including a model for the complete metabolic network of a pseudomonas)<sup>146</sup> with significant progress in simplifying networks,<sup>148</sup> modularizing them,<sup>149</sup> and better describing the dynamic nature of living cells;<sup>150</sup> cellular responses to external stimuli;<sup>151</sup> inter-cellular communication and cooperation with biomimetic microcapsules;<sup>152</sup> as well as whole-cell simulations for bacteria such as *E. coli* and *M. genitalium*.<sup>153</sup> <sup>154</sup>

27. Online tools made available over the past five years include: metabolic mapping software, for both whole metabolic networks and specific pathways;<sup>155</sup> platforms for comparative and functional genomics;<sup>156</sup> as well as the management and quality analysis of gene sequences.<sup>157</sup> Substantial investment has been made in developing new platforms designed to handle the volume of data produced by contemporary sequencing studies.<sup>158</sup>

28. Software suites are also available for use offline. Some of this software makes it easier to visualise complex biological information, including: genome sequence data:

<sup>137</sup> [http://www.bioone.org/doi/abs/10.2990/28\\_2\\_2](http://www.bioone.org/doi/abs/10.2990/28_2_2)

<sup>138</sup> <http://www.ncbi.nlm.nih.gov/pubmed/20231483>

<sup>139</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000117>

<sup>140</sup> <http://www.sciencemag.org/content/334/6062/1518>

<sup>141</sup> <http://www.biomedcentral.com/1752-0509/2/70>

<sup>142</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387229/>

<sup>143</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586632/>

<sup>144</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000118>

<sup>145</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18277381>

<sup>146</sup> <http://www.biomedcentral.com/1752-0509/2/66>

<sup>147</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000210>

<sup>148</sup> <http://www.biomedcentral.com/1752-0509/2/86>

<sup>149</sup> <http://www.biomedcentral.com/1752-0509/2/78>

<sup>150</sup> <http://www.biomedcentral.com/1752-0509/2/84>

<sup>151</sup> <http://web.mit.edu/newsoffice/2011/vivo-systems-biology-0323.html>

<sup>152</sup> <http://www.pnas.org/content/107/28/12417.abstract>

<sup>153</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1002010>

<sup>154</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000285>

<sup>155</sup> <http://nar.oxfordjournals.org/content/early/2011/05/28/nar.gkr433.full>

<sup>156</sup> <http://nar.oxfordjournals.org/content/early/2009/11/11/nar.gkp919.short>

<sup>157</sup> <http://www.biomedcentral.com/1471-2105/9/483/abstract>

<sup>158</sup> <http://www.genomeweb.com/informatics/nhgri-funds-new-sequencing-data-software-projects>

sequence assembly data; plasmid maps; gene expression; comparative and functional genomic data; transcription; secondary structure of RNA;<sup>159</sup> and biochemical networks.<sup>160</sup>

29. Other software has been developed for gene sequence analysis, including for: basic analysis; structural analysis; comparative analysis; the identification of operons;<sup>161</sup> the identification of repeats; the identification of signalling-relevant motifs; the identification of protein coding genes: as well as links with metabolic function and disease.<sup>162</sup>

30. Protein analysis tools have been developed to: take advantage of power graph analysis; identify protein functional modules; as well as for sequence analysis.<sup>163</sup>

31. Other tools have been released to help: annotate genomes; model thermodynamics of reactions; analyse metabolomic data; and identify opportunities to repurpose drugs.<sup>164</sup> There have also been efforts to make use of machine learning capacity to: identify highly designable protein sequences;<sup>165</sup> and study and validate essential enzymes in a metabolic network.<sup>166</sup>

32. There has also been notable progress in moving from descriptive and analytical tools to design tools to assist in designing and conducting experiments.<sup>167</sup> Design tools released over the last few years include those for: gene design: sequence design; gene network design; plasmid design; PCR design; protein design; as well metabolic pathway design.<sup>168</sup>

33. Combining advances in bioinformatics with those in characterization as well as high-throughput approaches, and robotics is beginning to enable automated research approaches. Advanced modelling software has been used to take partially-characterised biological systems (such as those from yeast functional genomics or drug screening) and through the use of artificial intelligence develop theories as to what the missing components of the system might be (both in terms of intermediaries and processes). These computational models can then be tested through laboratory experimentation, where all the equipment is controlled by the same computer that developed the theories. Beyond restocking basic expendable laboratory resources, the experiments are conducted without human intervention. The same computer then assesses the outcomes of the experiments and feeds the data back into the model and uses it to improve its theories. This process is then repeated until the system is fully elucidated. The ability of robot scientists to characterise biological systems has been assessed through empirical study. The robot scientists were provided partial data from well characterised networks and asked to deduce the rest. Results from these studies indicated that the robot scientists are capable of characterising discrete biological systems.<sup>169, 170, 171</sup> Not only do robot scientists promise to take much of the drudgery out of basic research but they might also help to address the current bottlenecks in characterizing parts, identifying function and interpreting raw data.

---

<sup>159</sup> <http://gvi.seas.harvard.edu/paper/multeesum-tool-comparative-spatial-and-temporal-gene-expression-data>

<sup>160</sup> <http://www.biomedcentral.com/1752-0509/2/104>

<sup>161</sup> <http://genomebiology.com/2008/9/12/R179>

<sup>162</sup> <http://www.biomedcentral.com/1752-0509/2/93>

<sup>163</sup> <http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1000108>

<sup>164</sup> <http://www.biomedcentral.com/1471-2105/9/470>

<sup>165</sup> <http://www.biomedcentral.com/1471-2105/9/487>

<sup>166</sup> <http://www.biomedcentral.com/1471-2105/9/487>

<sup>167</sup> <http://www.sciencemag.org/content/332/6031/816.abstract>

<sup>168</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238713/>

<sup>169</sup> <http://www.sciencemag.org/content/324/5923/85.abstract>

<sup>170</sup> <http://www.nature.com/nature/journal/v427/n6971/abs/nature02236.html>

<sup>171</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978088/>

## V. Converting biological information to digital data and back

34. If biology is becoming an information science then in part it is because of the ability to convert biological data into digital data and back again. Gene sequencing (reading the genetic code) enables us to move in one direction and gene synthesis (writing the genetic code) the other.<sup>172</sup> Capabilities to read and write genetic code are not new but capabilities in these areas have changed dramatically over the past five years.

35. Progress in sequencing has provided risks, benefits and challenges. It has added to the dual-use information previously available. For example, new pathogens, such as fungal plant pathogens, and the ricin-containing castor bean plant have been sequenced and the sequence data added to public databases. The same advances, however, help to strengthen public health capacity including molecular epidemiology, our understanding of pathogenesis, pathogen discovery and diagnosis, drug discovery, and vaccine development.<sup>173</sup> Recent events have demonstrated just how important this capacity can be. Advanced sequencing capacity enabled both the identification of an unknown agent responsible for a deadly disease outbreak in Germany in July 2011 and provided clues as to its origin and recent evolution. Increasing access to sequencing technology also raises the possibility of individuals having part (or all) of their genome sequenced and using the data to identify potential disease risks, which may in fact never be realised. Dealing with probabilities of disease is a complex task for highly trained medical professionals, allowing the general public access to such tools might well raise a series of conceptual, ethical and social challenges.<sup>174</sup>

36. Raw sequencing power has increased considerably over the past five years. Advances in technology continue to increase the throughput of automated gene sequencers. In December 2007, the Economist noted that a single gene sequencer was capable of sequencing the human genome (about 3 billion nucleotides in length) in two months. A day's output from a first generation sequencer could be replicated, at the end of 2007, in less than 10 seconds. Second generation sequencers, such as 454 sequencing, provided "higher throughput, simplified all in vitro sample preparation and the miniaturization of sequencing chemistries, enabling massively parallel sequencing reactions to be carried out at a scale and cost not previously possible".<sup>175</sup> Over the intervening years two sets of sequencers Illumina (Illumina GA IIX SOLiD 3.0 and Illumina Hi-Seq 2000) used different massively parallel sequencing approaches to increase sequence output per instrument run by another order of magnitude.<sup>176</sup>

37. By early 2011, third generation *ion torrent* sequencing was possible. These US\$50,000 machines "can read a bacterial genome in as little as two hours". The ion torrent machine takes advantage of semiconductor manufacturing techniques and integrated circuits and "uses cheaper, natural nucleotides, and senses the hydrogen ions (protons) that are released as each nucleotide is incorporated onto the complementary DNA".<sup>177</sup> Current versions of ion torrent machines are not as accurate as some of their predecessors and might be "better suited to achieving fast results in smaller scale projects, such as sequencing bacterial genomes or characterizing diseases by reading certain gene regions across many

<sup>172</sup> [http://www.rothamsted.ac.uk/ppi/pubs/kimhk/Beacham%20\\_et\\_al\\_2009\\_The\\_Biologist.pdf](http://www.rothamsted.ac.uk/ppi/pubs/kimhk/Beacham%20_et_al_2009_The_Biologist.pdf)

<sup>173</sup> <http://www.nejm.org/doi/full/10.1056/NEJMra1003071>

<sup>174</sup> <http://eon.businesswire.com/news/eon/20110727006628/en/Infectious-disease/pathogen-detection/e.-coli>

<sup>175</sup> <http://www.nature.com/nbt/journal/v26/n10/full/nbt1485.html>

<sup>176</sup> <http://www.nature.com/nature/journal/v470/n7333/full/nature09796.html>

<sup>177</sup> <http://www.nature.com/nature/journal/v475/n7356/full/nature10242.html>

patients".<sup>178</sup> At least one version of the machine currently comes with an iPod dock. Next generation sequencers, such as those based on nanopore technology, are already under development and promise to cut costs and boost output even further.<sup>179</sup> The ion proton sequencer was released in January 2012. This, according to the manufacturers, can sequence an entire human genome in a day for \$1000.<sup>180</sup>

38. A month later, rumours began to circulate of a new platform technology. Oxford Nanopore then announced the release of two machines the GridION and MinION. Both, according to the manufacturer, can read millions of bases per hour from samples with minimal preparations, including blood samples. The MinION is a disposable, memory-key sized unit which can be plugged into a computer for under \$1000.<sup>181</sup>

39. Instrument output is not the only measure of progress in sequencing. The cost per base of sequencing has continued to fall. When the preliminary sequences of the human genome were released in 2000, they had cost millions of dollars. It was reported in the *New Scientist* in March 2008 that a commercial biotechnology company in California, USA had sequenced a human genome for \$60,000, excluding labour. Over the past five years the cost per base has dropped by around four orders of magnitude. Advances in microfluidics look set to decrease the price even further. Equally, there are indications that the quality of sequence reads (in terms of lower error rates) have also gone up.<sup>182</sup> The current financial constraints and their impact on research funding could, however, reduce incentives that have driven recent advances.<sup>183</sup>

40. There are certainly rewards to be had for working on increased automation, accuracy and speed and decreased costs. In addition to the commercial applications, the X Prize Foundation, is now offering a \$10 million prize for the first team to sequence 100 individual genomes with an accuracy of 99%, within 10 days. Each sequence is to contain at least 98% of the genome and cost \$10,000 or less.<sup>184</sup>

41. This increased sequencing capacity has been used in a number of ways. It has enabled new types of projects to be attempted and as a result gathered different data sets,<sup>185</sup> including cataloguing sequences and their variation, assessing dynamic DNA and mixed genomes, investigating the epigenome and transcriptome, as well as combining different -omic approaches.

42. Health-related applications are increasingly common, for example, in diagnosing extremely rare genetic disorders,<sup>186</sup> working with hereditary conditions,<sup>187</sup> or infantile mitochondrial disease.<sup>188</sup> Over half of the genome sequences to date are part of disease specific projects.<sup>189</sup> For example, in 2001 the genome for the causative organism for plague was published throwing new light on the evolution of this pathogen.<sup>190</sup> Public funds are

---

<sup>178</sup> <http://www.nature.com/news/2011/110720/full/475278a.html>

<sup>179</sup> <http://pubs.acs.org/doi/abs/10.1021/nl103873a>

<sup>180</sup> <http://www.lifetechnologies.com/us/en/home/about-us/news-gallery/press-releases/2012/life-technologies-introduces-the-bechtol-io-protocol.html>

<sup>181</sup> <http://www.nature.com/nbt/journal/v30/n4/full/nbt0412-295.html>

<sup>182</sup> <http://www.technologyreview.com/news/419258/the-30-genome/>

<sup>183</sup> <http://www.nature.com/news/2011/111101/full/479017a.html>

<sup>184</sup> <http://www.technologyreview.com/news/419258/the-30-genome/>

<sup>185</sup> <http://www.nature.com/nbt/journal/v26/n10/full/nbt1494.html>

<sup>186</sup> <http://www.nature.com/news/2011/111005/full/478022a.html>

<sup>187</sup> <http://www.technologyreview.com/review/412209/a-hole-in-the-genome/>

<sup>188</sup> <http://stm.sciencemag.org/content/4/118/118ra10.abstract>

<sup>189</sup> <http://www.pnas.org/content/108/4/1513.full>

<sup>190</sup> <http://www.nature.com/nature/journal/v478/n7370/full/nature10549.html>

being invested to develop medical applications based on advanced sequencing capacity.<sup>191</sup> Companies and service providers have already begun to work on tools and platforms.<sup>192,193</sup>

43. Advanced sequencing capacity can be found on every continent and, in line with broader trends in biotechnology, increasingly in developing countries. An interactive map created by the Bacterial Pathogenomics research group at the University of Birmingham in the United Kingdom illustrates the global spread.<sup>194</sup>

44. Despite the distribution of sequencers, there is less geographical balance in the genes being sequenced. There has been an exponential growth in the number of human genomes that have been sequenced. Only two had been sequenced at the Sixth Review Conference in 2006. By the end of 2011, it was estimated that over 30,000 human genomes had been sequenced. The majority of these, however, are from Caucasian or Asian individuals; very few African and South American genomes have been complete.<sup>195</sup> Similar disparities exist in medical genomics and there have been calls to expand the sequencing of other ethnic groups.

45. There has also been progress in ability to understand and use sequence data. Genome mining techniques have started to identify useful compounds encoded within sequence data.<sup>196</sup> Genome wide analysis and association studies have: improved linkages between sequence data and metabolomics data; linked genetic variations at specific loci with particular diseases;<sup>197</sup> led to personal genome scans which can provide risk indicators for specific diseases;<sup>198</sup> and provided insights into mutation rates. Deep sequencing has also made steady headway in helping to determine gene function.<sup>199</sup>

46. Trends in synthesis capacity mirror those for sequencing. There have been technical improvements in the ability to produce longer strands of genetic material. New assembly techniques make it easier and faster to combine short fragments into long sequences.<sup>200</sup> These techniques were used in 2010 to build a piece of DNA with over one million base pairs. The cost of having gene length fragments commercially synthesized also continues to fall (even faster than the costs of synthesizing smaller oligonucleotide sequences).<sup>201</sup> Quality seems to be increasing, with both recursive and re-sequencing approaches providing for more effective error correction.<sup>202</sup> For example, in February 2012, Integrated DNA Technologies introduced a new service, which it claims will deliver double-stranded, sequence verified, genomic blocks up to 500bp within 3-4 working days with a 33% decrease in costs over similar services in the past.<sup>203</sup> Days later the company announced a new partnership with Synthetic Genomics to use this platform to offer commercial production of custom, synthetic, double-stranded genomic fragments up to 5000 base pairs.<sup>204</sup>

<sup>191</sup> <http://www.nature.com/news/funds-dedicated-to-personalized-genetics-1.9565>

<sup>192</sup> <http://www.genomeweb.com/sequencing/life-tech-opgen-combine-technologies-outbreak-surveillance>

<sup>193</sup> <http://www.guardian.co.uk/science/2011/dec/28/mayo-clinic-genomes-personalised-care>

<sup>194</sup> <http://pathogenomics.bham.ac.uk/hts/>

<sup>195</sup> <http://www.nature.com/nature/journal/v456/n7218/full/456049a.html>

<sup>196</sup> [http://www.microbeworld.org/index.php?option=com\\_jlibrary&view=article&id=4343](http://www.microbeworld.org/index.php?option=com_jlibrary&view=article&id=4343)

<sup>197</sup> <http://www.nature.com/nature/journal/v477/n7362/full/nature10354.html>

<sup>198</sup> <http://www.nature.com/nature/journal/v456/n7223/full/nature07631.html>

<sup>199</sup> <http://www.ncbi.nlm.nih.gov/pubmed/21623355>

<sup>200</sup> <http://www.nature.com/nmeth/journal/v6/n5/full/nmeth.1318.html>

<sup>201</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424292/>

<sup>202</sup> <http://www.nature.com/nmeth/journal/v8/n2/full/nmeth0211-114.html>

<sup>203</sup> <http://eu.idtdna.com/pages/mobile/news/2012/01/31/integrated-dna-technologies-introduces-gblockstm-gene-fragments>

<sup>204</sup> <http://manufacturing.pharmaceutical-business-review.com/news/sgi-idt-partner-to-manufacture->

47. The projects being attempted with synthesis technologies are also becoming more sophisticated. At the time of the last review conference, cutting edge application was taking place in viral settings, May 2010 saw the chemical synthesis of a functional genome capable of controlling a bacterial cell,<sup>205</sup> and by November 2010 similar approaches were being used in animal models (although to chemically synthesize the genome of mitochondria, not the mouse in which it is found).<sup>206</sup> By September 2011, this had moved again to synthesis of part of the chromosome of a eukaryote.<sup>207</sup>

## VI. Generic enabling technologies

48. Underpinning many of the advances discussed throughout this paper are a range of technologies that make it easier, cheaper, faster or more reliable to do many of the basic procedures and practices involved in expanding the limits of understanding and creating new applications. Other advances have allowed scientists to do things that were previously unattainable.<sup>208</sup> Significant enabling technologies developed over the past five years included:

- (a) A simpler, cheaper and more reliable way of forming carbon-hydrogen bonds important in biochemical synthesis;<sup>209</sup>
- (b) Gene profiling and agent identification using quantitative PCR;<sup>210</sup>
- (c) Faster and more accurate ways of determining the three dimensional structure of biological macromolecules using new synchrotron light sources;<sup>211</sup>
- (d) Tools to study the binding and unbinding of individual strands of DNA through a combination of fluorescent microscopy and optical traps;<sup>212</sup>
- (e) An high-throughput tool for in vivo analysis of bioactive small molecules important for modulating protein function and important leads for drug discovery;<sup>213</sup>
- (f) New ways to create diverse small molecule drug candidate libraries enabling high-throughput drug discovery;<sup>214</sup>
- (g) Real-time, multi-parameter analysis of single immune cells using single cell mass cytometry (tools used to make measurement of impurities in superconductors);<sup>215</sup>
- (h) Better imaging tools, including digital holographic microscopes,<sup>216</sup> three-dimensional isotropic imaging of living cells using Bessel beam plane illumination,<sup>217</sup> as well as sub-diffraction-limit imaging by stochastic optical reconstruction microscopy

---

synthetic-gene-products-030212

<sup>205</sup> <http://www.sciencemag.org/content/329/5987/52.abstract>

<sup>206</sup> <http://www.nature.com/nmeth/journal/v7/n11/full/nmeth.1515.html>

<sup>207</sup> <http://www.ncbi.nlm.nih.gov/pubmed/21918511>

<sup>208</sup> [http://www.nap.edu/catalog.php?record\\_id=12601](http://www.nap.edu/catalog.php?record_id=12601)

<sup>209</sup> <http://www.scripps.edu/news/press/2009/120309.html>

<sup>210</sup> <http://www.nature.com/nmeth/journal/v8/n3/full/nmeth0311-207.html>

<sup>211</sup> <http://connection.ebscohost.com/c/articles/59207776/illuminating-science-how-synchrotrons-are-revolutionising-structural-biology>

<sup>212</sup> [http://news.illinois.edu/news/11/0302DNA\\_TKHa\\_YannChemla.html](http://news.illinois.edu/news/11/0302DNA_TKHa_YannChemla.html)

<sup>213</sup> <http://www.ncbi.nlm.nih.gov/pubmed/18622389>

<sup>214</sup> <http://www.nature.com/nature/journal/v457/n7226/full/457153a.html>

<sup>215</sup> <http://www.sciencemag.org/content/332/6030/687.abstract>

<sup>216</sup> [http://www.nap.edu/catalog.php?record\\_id=12821](http://www.nap.edu/catalog.php?record_id=12821)

<sup>217</sup> <http://www.ncbi.nlm.nih.gov/pubmed/21378978>

(STORM), which enables the simultaneous imaging of multiple molecules in living cells and has been used to examine the changes in concentration of proteins in the membranes of immune cells when they encounter toxins;<sup>218</sup>

(i) Improvements in temporal analysis of gene expression using short-time series microarrays which enable expression to be tracked more accurately over time, perhaps as a system is perturbed;<sup>219</sup>

(j) A way to specifically target endogenous gene sequences to introduce mutations, tags or new sequences via optimized transcription-activator-like effector (TALEs);<sup>220</sup>

(k) Tools for single cell analysis, including its genome, transcriptome, metabolome, and peptidome;<sup>221</sup>

(l) The use of quantum dots to tag and track individual viruses;<sup>222</sup>

(m) A much faster and simplified way of compiling short sections of genetic material together to make longer strands, via the Gibson assembly technique;<sup>223</sup>

(n) Better optimized protein production in *E.coli* through continuous directed evolution of gene encoded molecules via phage-assisted continuous evolution (PACE);<sup>224</sup>

(o) Genome editing tools for small-scale genome engineering by the programming and evolution of cells by simultaneously targeting many locations on their chromosome via multiplex automated genome engineering (MAGE)<sup>225</sup> and MAGE codon modifications to provide for large-scale genome via hierarchical conjugative assembly genome engineering (CAGE);<sup>226 227</sup>

(p) Inserting genetic material into cells, by either using a gene gun (which was created prior to the last review conference but has been improved considerably since) or via a non-viral plasmid;<sup>228</sup>

(q) More sophisticated microfluidic applications, such as the addition of optical pumps or better system integration, which improves the utility of a lab-on-a-chip;<sup>229</sup>

(r) Cell free systems designed to produce encoded proteins from synthesised DNA via nucleic acid programmable protein arrays (NAPPA);<sup>230</sup>

(s) A way to control cell function using light (which provides targeted, fast control of precisely defined events in biological systems) through optogenetics;<sup>231</sup>

<sup>218</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700296/>

<sup>219</sup> <http://www.biomedcentral.com/1752-0509/2/58>

<sup>220</sup> <http://www.nature.com/nmeth/journal/v8/n3/full/nmeth0311-197.html>

<sup>221</sup> <http://www.nature.com/nmeth/journal/v8/n4s/full/nmeth0411-S1.html>

<sup>222</sup> <http://www.newscientist.com/article/dn14675-viral-manoevres-revealed-by-surveillance-system.html>

<sup>223</sup> <http://www.nature.com/nmeth/journal/v6/n5/full/nmeth.1318.html>

<sup>224</sup> <http://www.nature.com/nbt/journal/v29/n6/full/nbt.1884.html>

<sup>225</sup> <http://nextbigfuture.com/2010/08/george-churchs-multiplex-automated.html>

<sup>226</sup> <http://phys.org/news/2011-07-genome.html>

<sup>227</sup> <http://www.sciencemag.org/content/333/6040/348.abstract>

<sup>228</sup> <http://discover-decouvrir.cisti-icist.nrc-cnrc.gc.ca/eng/article/?id=17719349>

<sup>229</sup> <http://www.ncbi.nlm.nih.gov/pubmed/21612614>

<sup>230</sup> <http://nextbigfuture.com/2008/02/any-protein-can-be-made-from.html>

<sup>231</sup> <http://www.nature.com/nmeth/journal/v8/n1/abs/nmeth.f.325.html>

- (t) Approaches for tissue engineering and assembling three dimensional biological structures and using standardised blocks or through printing;<sup>232</sup>
- (u) Automated research suites designed to enable high-throughput screening campaigns, including those intended for use under BSL-2 conditions;<sup>233</sup>
- (v) Increasingly comprehensive sets of normal data stored in biobanks, including genetic information and blood samples as well as medical and family histories;<sup>234</sup>
- (w) A new way to trap and manipulate micro-scale objects using mobile micro-vortices;<sup>235</sup>
- (x) A protocol for using multi-isotope imaging mass spectrometry (MIMS) in living cells at the sub-micrometer range;<sup>236</sup>
- (y) A new method for assessing the "drug-likeness" of compounds;<sup>237</sup>
- (z) High-throughput screening tools to screen libraries of compounds for biological activity based upon improvements in microfluidics.<sup>238</sup>

---

<sup>232</sup> <http://web.mit.edu/newsoffice/2010/tissue-legos-0513.html>

<sup>233</sup> [http://www.highresbio.com/pdf/HighRes\\_Bio\\_in\\_NatureMethods0908\\_843.pdf](http://www.highresbio.com/pdf/HighRes_Bio_in_NatureMethods0908_843.pdf)

<sup>234</sup> <http://www.nature.com/nbt/journal/v29/n6/full/nbt.1884.html>

<sup>235</sup> <http://pubs.acs.org/doi/abs/10.1021/nl2032487>

<sup>236</sup> <http://www.nature.com/nature/journal/v481/n7382/full/481454a.html>

<sup>237</sup> <http://www.nature.com/nature/journal/v481/n7382/full/481455a.html>

<sup>238</sup> <http://www.nature.com/nature/journal/v483/n7387/full/483043a.html>